We thank Dr Alatorre and co-authors for their letter [1] regarding our manuscript entitled “Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison”, which was published in the November 1, 2012 issue of Applied Health Economics and Health Policy [2].
We have conducted a thorough review of the manuscript and supportive study analyses from which it stems. We have found that some numbers in Table III were transposed in the published manuscript. The erratum [3] is published to correct these errors.
We apologize for the errors and confirm that these errors are typographical in nature and do not affect the results, discussion or conclusion in the originally published manuscript [2].
Footnotes
This Correspondence refers to the article at doi:10.1007/s40258-013-0024-2
References
- 1.Alatorre CI, Haynes V, Faries D, Upadhyaya H, Kelsey D. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison [letter] Appl Health Econ Health Policy. 2013 doi: 10.1007/s40258-013-0024-2. [DOI] [PubMed] [Google Scholar]
- 2.Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy. 2012;10(6):381–395. doi: 10.1007/BF03261873. [DOI] [PubMed] [Google Scholar]
- 3.Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V. Erratum to: cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy. 2013 doi: 10.1007/BF03261873. [DOI] [PubMed] [Google Scholar]